Radioconjugate drugs—combining radionuclides with targeting ligands such as antibodies, peptides, or small molecules via chelators and linkers—represent a cutting-edge approach in precision medicine. By delivering radionuclides directly to disease sites, they enable targeted tumor ablation or highly accurate diagnostic imaging, revolutionizing both therapy and diagnostics.

To enhance the stability, solubility, and pharmacokinetics of your radioconjugates, Sinopeg offers high-purity, monodisperse polyethylene glycol (PEG) derivatives. These well-defined PEG linkers ensure improved conjugation efficiency, reduced immunogenicity, and optimized in vivo performance—key factors for developing safe and effective radiopharmaceuticals.

Whether you are designing novel radioligands or optimizing existing constructs, Sinopeg’s tailored PEG solutions can accelerate your R&D and help bring more precise, impactful treatments to patients.

Reach out to explore how we can support your next-generation radioconjugate projects!

Various Kingds And Grades Of Such Monodispersed Are Readily Avaliable| SINOPEG